Genetics of pleiotropic effects of dexamethasone

Laura B. Ramsey, Stan Pounds, Cheng Cheng, Xueyuan Cao, Wenjian Yang, Colton Smith, Seth E. Karol, Chengcheng Liu, John C. Panetta, Hiroto Inaba, Jeffrey E. Rubnitz, Monika L. Metzger, Raul C. Ribeiro, John T. Sandlund, Sima Jeha, Ching Hon Pui, William E. Evans, Mary V. Relling

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: Glucocorticoids such as dexamethasone have pleiotropic effects, including desired antileukemic, anti-inflammatory, or immunosuppressive effects, and undesired metabolic or toxic effects. The most serious adverse effects of dexamethasone among patients with acute lymphoblastic leukemia are osteonecrosis and thrombosis. To identify inherited genomic variation involved in these severe adverse effects, we carried out genome-wide association studies (GWAS) by analyzing 14 pleiotropic glucocorticoid phenotypes in 391 patients with acute lymphoblastic leukemia. Patients and methods: We used the Projection Onto the Most Interesting Statistical Evidence integrative analysis technique to identify genetic variants associated with pleiotropic dexamethasone phenotypes, stratifying for age, sex, race, and treatment, and compared the results with conventional single-phenotype GWAS. The phenotypes were osteonecrosis, central nervous system toxicity, hyperglycemia, hypokalemia, thrombosis, dexamethasone exposure, BMI, growth trajectory, and levels of cortisol, albumin, and asparaginase antibodies, and changes in cholesterol, triglycerides, and low-density lipoproteins after dexamethasone. Results: The integrative analysis identified more pleiotropic single nucleotide polymorphism variants (P=1.46×10 -215), and these variants were more likely to be in gene-regulatory regions (P=1.22×10 -6) than traditional single-phenotype GWAS. The integrative analysis yielded genomic variants (rs2243057 and rs6453253) in F2RL1, a receptor that functions in hemostasis, thrombosis, and inflammation, which were associated with pleiotropic effects, including osteonecrosis and thrombosis, and were in regulatory gene regions. Conclusion: The integrative pleiotropic analysis identified risk variants for osteonecrosis and thrombosis not identified by single-phenotype analysis that may have importance for patients with underlying sensitivity to multiple dexamethasone adverse effects.

Original languageEnglish (US)
Pages (from-to)294-302
Number of pages9
JournalPharmacogenetics and Genomics
Volume27
Issue number8
DOIs
StatePublished - Jan 1 2017

Fingerprint

Dexamethasone
Osteonecrosis
Thrombosis
Phenotype
Genome-Wide Association Study
Nucleic Acid Regulatory Sequences
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Glucocorticoids
Asparaginase
Hypokalemia
Poisons
Regulator Genes
Immunosuppressive Agents
Hemostasis
Hyperglycemia
LDL Cholesterol
Single Nucleotide Polymorphism
Hydrocortisone
Albumins
Anti-Inflammatory Agents

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Ramsey, L. B., Pounds, S., Cheng, C., Cao, X., Yang, W., Smith, C., ... Relling, M. V. (2017). Genetics of pleiotropic effects of dexamethasone. Pharmacogenetics and Genomics, 27(8), 294-302. https://doi.org/10.1097/FPC.0000000000000293

Genetics of pleiotropic effects of dexamethasone. / Ramsey, Laura B.; Pounds, Stan; Cheng, Cheng; Cao, Xueyuan; Yang, Wenjian; Smith, Colton; Karol, Seth E.; Liu, Chengcheng; Panetta, John C.; Inaba, Hiroto; Rubnitz, Jeffrey E.; Metzger, Monika L.; Ribeiro, Raul C.; Sandlund, John T.; Jeha, Sima; Pui, Ching Hon; Evans, William E.; Relling, Mary V.

In: Pharmacogenetics and Genomics, Vol. 27, No. 8, 01.01.2017, p. 294-302.

Research output: Contribution to journalArticle

Ramsey, LB, Pounds, S, Cheng, C, Cao, X, Yang, W, Smith, C, Karol, SE, Liu, C, Panetta, JC, Inaba, H, Rubnitz, JE, Metzger, ML, Ribeiro, RC, Sandlund, JT, Jeha, S, Pui, CH, Evans, WE & Relling, MV 2017, 'Genetics of pleiotropic effects of dexamethasone', Pharmacogenetics and Genomics, vol. 27, no. 8, pp. 294-302. https://doi.org/10.1097/FPC.0000000000000293
Ramsey, Laura B. ; Pounds, Stan ; Cheng, Cheng ; Cao, Xueyuan ; Yang, Wenjian ; Smith, Colton ; Karol, Seth E. ; Liu, Chengcheng ; Panetta, John C. ; Inaba, Hiroto ; Rubnitz, Jeffrey E. ; Metzger, Monika L. ; Ribeiro, Raul C. ; Sandlund, John T. ; Jeha, Sima ; Pui, Ching Hon ; Evans, William E. ; Relling, Mary V. / Genetics of pleiotropic effects of dexamethasone. In: Pharmacogenetics and Genomics. 2017 ; Vol. 27, No. 8. pp. 294-302.
@article{168e36c7066e48619e87cf2ad7543506,
title = "Genetics of pleiotropic effects of dexamethasone",
abstract = "Objectives: Glucocorticoids such as dexamethasone have pleiotropic effects, including desired antileukemic, anti-inflammatory, or immunosuppressive effects, and undesired metabolic or toxic effects. The most serious adverse effects of dexamethasone among patients with acute lymphoblastic leukemia are osteonecrosis and thrombosis. To identify inherited genomic variation involved in these severe adverse effects, we carried out genome-wide association studies (GWAS) by analyzing 14 pleiotropic glucocorticoid phenotypes in 391 patients with acute lymphoblastic leukemia. Patients and methods: We used the Projection Onto the Most Interesting Statistical Evidence integrative analysis technique to identify genetic variants associated with pleiotropic dexamethasone phenotypes, stratifying for age, sex, race, and treatment, and compared the results with conventional single-phenotype GWAS. The phenotypes were osteonecrosis, central nervous system toxicity, hyperglycemia, hypokalemia, thrombosis, dexamethasone exposure, BMI, growth trajectory, and levels of cortisol, albumin, and asparaginase antibodies, and changes in cholesterol, triglycerides, and low-density lipoproteins after dexamethasone. Results: The integrative analysis identified more pleiotropic single nucleotide polymorphism variants (P=1.46×10 -215), and these variants were more likely to be in gene-regulatory regions (P=1.22×10 -6) than traditional single-phenotype GWAS. The integrative analysis yielded genomic variants (rs2243057 and rs6453253) in F2RL1, a receptor that functions in hemostasis, thrombosis, and inflammation, which were associated with pleiotropic effects, including osteonecrosis and thrombosis, and were in regulatory gene regions. Conclusion: The integrative pleiotropic analysis identified risk variants for osteonecrosis and thrombosis not identified by single-phenotype analysis that may have importance for patients with underlying sensitivity to multiple dexamethasone adverse effects.",
author = "Ramsey, {Laura B.} and Stan Pounds and Cheng Cheng and Xueyuan Cao and Wenjian Yang and Colton Smith and Karol, {Seth E.} and Chengcheng Liu and Panetta, {John C.} and Hiroto Inaba and Rubnitz, {Jeffrey E.} and Metzger, {Monika L.} and Ribeiro, {Raul C.} and Sandlund, {John T.} and Sima Jeha and Pui, {Ching Hon} and Evans, {William E.} and Relling, {Mary V.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/FPC.0000000000000293",
language = "English (US)",
volume = "27",
pages = "294--302",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Genetics of pleiotropic effects of dexamethasone

AU - Ramsey, Laura B.

AU - Pounds, Stan

AU - Cheng, Cheng

AU - Cao, Xueyuan

AU - Yang, Wenjian

AU - Smith, Colton

AU - Karol, Seth E.

AU - Liu, Chengcheng

AU - Panetta, John C.

AU - Inaba, Hiroto

AU - Rubnitz, Jeffrey E.

AU - Metzger, Monika L.

AU - Ribeiro, Raul C.

AU - Sandlund, John T.

AU - Jeha, Sima

AU - Pui, Ching Hon

AU - Evans, William E.

AU - Relling, Mary V.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objectives: Glucocorticoids such as dexamethasone have pleiotropic effects, including desired antileukemic, anti-inflammatory, or immunosuppressive effects, and undesired metabolic or toxic effects. The most serious adverse effects of dexamethasone among patients with acute lymphoblastic leukemia are osteonecrosis and thrombosis. To identify inherited genomic variation involved in these severe adverse effects, we carried out genome-wide association studies (GWAS) by analyzing 14 pleiotropic glucocorticoid phenotypes in 391 patients with acute lymphoblastic leukemia. Patients and methods: We used the Projection Onto the Most Interesting Statistical Evidence integrative analysis technique to identify genetic variants associated with pleiotropic dexamethasone phenotypes, stratifying for age, sex, race, and treatment, and compared the results with conventional single-phenotype GWAS. The phenotypes were osteonecrosis, central nervous system toxicity, hyperglycemia, hypokalemia, thrombosis, dexamethasone exposure, BMI, growth trajectory, and levels of cortisol, albumin, and asparaginase antibodies, and changes in cholesterol, triglycerides, and low-density lipoproteins after dexamethasone. Results: The integrative analysis identified more pleiotropic single nucleotide polymorphism variants (P=1.46×10 -215), and these variants were more likely to be in gene-regulatory regions (P=1.22×10 -6) than traditional single-phenotype GWAS. The integrative analysis yielded genomic variants (rs2243057 and rs6453253) in F2RL1, a receptor that functions in hemostasis, thrombosis, and inflammation, which were associated with pleiotropic effects, including osteonecrosis and thrombosis, and were in regulatory gene regions. Conclusion: The integrative pleiotropic analysis identified risk variants for osteonecrosis and thrombosis not identified by single-phenotype analysis that may have importance for patients with underlying sensitivity to multiple dexamethasone adverse effects.

AB - Objectives: Glucocorticoids such as dexamethasone have pleiotropic effects, including desired antileukemic, anti-inflammatory, or immunosuppressive effects, and undesired metabolic or toxic effects. The most serious adverse effects of dexamethasone among patients with acute lymphoblastic leukemia are osteonecrosis and thrombosis. To identify inherited genomic variation involved in these severe adverse effects, we carried out genome-wide association studies (GWAS) by analyzing 14 pleiotropic glucocorticoid phenotypes in 391 patients with acute lymphoblastic leukemia. Patients and methods: We used the Projection Onto the Most Interesting Statistical Evidence integrative analysis technique to identify genetic variants associated with pleiotropic dexamethasone phenotypes, stratifying for age, sex, race, and treatment, and compared the results with conventional single-phenotype GWAS. The phenotypes were osteonecrosis, central nervous system toxicity, hyperglycemia, hypokalemia, thrombosis, dexamethasone exposure, BMI, growth trajectory, and levels of cortisol, albumin, and asparaginase antibodies, and changes in cholesterol, triglycerides, and low-density lipoproteins after dexamethasone. Results: The integrative analysis identified more pleiotropic single nucleotide polymorphism variants (P=1.46×10 -215), and these variants were more likely to be in gene-regulatory regions (P=1.22×10 -6) than traditional single-phenotype GWAS. The integrative analysis yielded genomic variants (rs2243057 and rs6453253) in F2RL1, a receptor that functions in hemostasis, thrombosis, and inflammation, which were associated with pleiotropic effects, including osteonecrosis and thrombosis, and were in regulatory gene regions. Conclusion: The integrative pleiotropic analysis identified risk variants for osteonecrosis and thrombosis not identified by single-phenotype analysis that may have importance for patients with underlying sensitivity to multiple dexamethasone adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=85021079930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021079930&partnerID=8YFLogxK

U2 - 10.1097/FPC.0000000000000293

DO - 10.1097/FPC.0000000000000293

M3 - Article

VL - 27

SP - 294

EP - 302

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 8

ER -